Browse the evidence

Barriers to providing advice on specific dietary patterns for T2DM include safety and compliance challenges.

Dietitians should be aware of and address safety and compliance issues when advising patients.

Common cardiovascular conditions, such as heart failure with preserved ejection fraction, can be conceptualized as a consequence of accelerated aging.

Understanding the link between aging and heart failure can guide prevention and management strategies.

Genetic predisposition to higher waist-to-hip ratio adjusted for BMI (WHRadjBMI) predicts an increase in waist circumference after weight loss.

Practitioners should consider genetic predisposition when assessing potential waist circumference changes after weight loss.

Genetic predisposition to higher BMI does not predict weight regain after weight loss.

Genetic factors related to BMI may not be useful for predicting weight regain, focusing instead on abdominal obesity genetics.

Genetic effects on abdominal obesity may be more pronounced than those on general obesity during weight regain.

Understanding the differential impact of genetics on abdominal versus general obesity can inform targeted interventions.

Remission of diabetes may not be permanent and can result in glycemic relapse over time.

Clinicians should communicate the potential for relapse when discussing remission with patients.

Companies can profit from CCT programs by selling enrollment as self-commitment devices.

Businesses can leverage CCT programs as a market opportunity while promoting healthier behaviors.

There is a need for sport event organizers to question and challenge claims of health promotion.

Sport organizations should critically evaluate their health promotion strategies and claims.

An inverse relationship was found between the sitting height to total height ratio and the SDL:CDL strength ratio.

Individuals with longer torsos may benefit more from the SDL.

NN1706 lowers body weight & improves glycemic control in obese rodents and monkeys.

NN1706 may also be beneficial for weight management and glycemic control in animal models of obesity.

Increased heart rate was observed across NN1706 treatment cohorts.

Clinicians should monitor heart rate in patients receiving NN1706 treatment.

There is an urgent need to develop effective therapies for diabetes to reduce the risks of serious complications.

Healthcare systems should prioritize the development of new diabetes therapies.

The most common components of metabolic syndrome in the cohort were abdominal obesity and elevated blood pressure.

Understanding common MetS components can guide targeted interventions.

Challenges with GLP-1s include side effects, nutritional deficiencies, and low long-term adherence.

Clinicians should be aware of and manage these challenges when prescribing GLP-1s.

In postmenopausal females with type 2 diabetes, an intensive lifestyle intervention decreased estradiol levels by 15% and bioavailable testosterone by 13% at year 1.

Practitioners should consider the hormonal changes in females when implementing weight loss interventions.

Sleep restriction reduced fat oxidation during high-dose insulin infusion in postmenopausal women.

Practitioners should be aware that sleep restriction may impair fat oxidation in this population.

Low energy availability did not enhance performance when expressed relative to body mass.

Performance assessments should consider body mass to accurately evaluate the effects of energy availability.

In the intervention group, there was statistically significantly higher Part B spending compared to the control group (difference, $513; P = .02).

Practitioners should be aware that while overall spending did not decrease, specific areas like Part B spending increased.

No evidence of a relationship was found between RIR accuracy and biological sex, years of RT experience, or relative bench press strength.

RIR accuracy can be considered independent of these demographic and experiential factors.

GLP-1 receptor agonists were originally developed as glucose lowering agents.

Understanding the original purpose of GLP-1 receptor agonists can inform their use in weight management.

Tirzepatide has similar gastrointestinal adverse reactions and contraindications as traditional GLP-1 receptor agonists.

Clinicians should be aware of the potential for similar side effects when prescribing tirzepatide.

Relevant articles on cardiovascular disease prevention in obesity, atherogenic dyslipidaemia, and chronic kidney disease have been included.

Practitioners should consider the impact of obesity and related conditions on cardiovascular health.

Rapid weight loss induced by semaglutide can lead to noticeable facial volume loss and the appearance of a prematurely aged face, referred to as 'Ozempic face.'

Healthcare providers should be aware of the potential cosmetic implications of semaglutide use for weight loss.

The characteristics of 'Ozempic face' occur in people much younger than what is seen with the natural aging process.

Clinicians should consider age-related factors when assessing patients for semaglutide treatment.